Join the Actinic Keratosis group to help and get support from people like you.
Actinic Keratosis News
Related terms: Keratoses
Adding 3D Total Body Photography to Usual Care Increases Rate of Skin Excisions
WEDNESDAY, March 26, 2025 – The addition of three-dimensional (3D) total-body photography (TBP) and sequential digital dermoscopy imaging (SDDI) via teledermatology to usual care increases the...
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) – Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the commercialization of dermatologic pro...
FDA Approves Almirall’s Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on Expanded Area of Face or Scalp
MALVERN, PA. June 10, 2024 – Almirall, a global pharmaceutical company dedicated to medical dermatology, announced today that the U.S. Food and Drug Administration (FDA) has approved Almirall’s r...
FDA Approves Klisyri (tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp
BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) – Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies...
Biofrontera Announces U.S. FDA Approval of Ameluz and Activating BF-RhodoLED Device for Treatment of Actinic Keratosis
Leverkusen, Germany, May 11, 2016 – Biofrontera AG (FSE: B8F), the specialist for the treatment of sun-induced skin cancer, today announced that the U.S. Food and Drug Administration (FDA) has g...
FDA Medwatch Alert: Picato (ingenol mebutate) Gel: Drug Safety Communication - FDA Warns of Severe Adverse Events, Requires Label Changes
ISSUE: FDA is warning about reports of severe allergic reactions and herpes zoster (shingles) associated with the use of Picato gel (ingenol mebutate). FDA received reports of cases involving severe...
FDA Approves Picato (ingenol mebutate) Gel, the First and Only Topical Actinic Keratosis (AK) Therapy With 2 or 3 Consecutive Days of Once-Daily Dosing
PARSIPPANY, N.J., January 25, 2012, 2012 /PRNewswire/ – Leo Pharma announced today that the U.S. Food and Drug Administration (FDA) approved Picato (ingenol mebutate) gel (0.015%, 0.05%) for the...
FDA Approves Zyclara (imiquimod) Cream, 2.5% for the Treatment of Actinic Keratoses
BRISTOL, Tenn.--(BUSINESS WIRE)--Jul 18, 2011 - Graceway Pharmaceuticals, LLC (Graceway) announced today that the Food and Drug Administration (FDA) has approved Zyclara Cream, 2.5% for the treatment...
FDA Approves Zyclara (imiquimod) Cream, 3.75% for the Treatment of Actinic Keratoses
BRISTOL, Tenn., March 26 /PRNewswire/ – Graceway Pharmaceuticals announced today that the Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Zyclara, determining it...